As such, in the neonatal setting the diagnostic challenge is to distinguish forms of NSHPT based on homozygous or compound heterozygous mutations in CaSR, which require aggressive and definite calcium and PTH suppressive measures, from milder forms such as NHPT which will resolve within the first months of life. This evidence concerns the gene PTH and neonatal severe primary hyperparathyroidism.